Preparation method of isoindolinone derivatives, novel intermediate used in the method and preparation method thereof

Compounds that promote the production of nerve growth factor were successfully synthesized through Mannich reaction, acid-base reaction, allyl halide reaction and Claisen rearrangement reaction, which solves the problem of lack of synthetic methods in the prior art and provides a treatment option for neurodegenerative diseases.

CN115836059BActive Publication Date: 2024-11-08CNG BIO CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080091620.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-12-03
Filing Date
2020-12-03
Publication Date
2024-11-08
Estimated Expiration
2040-12-03

AI Technical Summary

Technical Problem

Existing technologies do not provide effective synthetic methods for preparing compounds with nerve growth factor-promoting activity for the treatment of neurodegenerative diseases.

Method used

The compound 4-hydroxy-5-(2-hydroxyethyl)-6-methoxy-2-phenylethylisoindoline-1-one of formula 1 was prepared by a series of chemical reactions, including the Mannich reaction, acid-base reaction, allyl halide reaction and Claisen rearrangement reaction.

Benefits of technology

The efficient synthesis of compound of chemical formula 1 was achieved, which promoted the production of nerve growth factor and provided a potential treatment option for neurological diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003725571000000011
    Figure BDA0003725571000000011
  • Figure BDA0003725571000000021
    Figure BDA0003725571000000021
  • Figure BDA0003725571000000031
    Figure BDA0003725571000000031
Patent Text Reader

Abstract

The present invention relates to a method for preparing an isoindolinone derivative represented by Chemical Formula 1, a novel intermediate used in the method and a method for preparing the same.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a method for preparing an isoindolinone derivative represented by Chemical Formula 1, a novel intermediate used in the method and a method for preparing the same.

[0002] Chemical formula 1

[0003] Background Art

[0004] Recently, with the rapid increase in the elderly population, the number of patients with neurodegenerative diseases has also increased, and the prevention and treatment of the disease have also received increasing attention. Neurodegenerative diseases are diseases that induce movement disorders, memory disorders, cognitive disorders and other symptoms due to the reduction or disappearance of nerve cell functions. Not only in nervous system diseases, but also in the brains of normal adults, a large number of nerve cells undergo apoptosis every day. With aging, the number of apoptotic nerve cells increases exponentially (Yuan and Yankner, Nature. 407, 802-809, 2000).

[0005] The main diseases belonging to neurodegenerative diseases include Alzheimer's disease, Parkinson's disease, Lou Gehrig's disease, Huntington's disease, etc. The pathogenesis of these diseases has not yet been fully understood. The therapeutic agents for Alzheimer's disease use acetylcholinesterase inhibitors or N-methyl-D-aspartate (NMDA, N-methyl-D-aspartate) receptor antagonists, etc., the therapeutic agents for Parkinson's disease use levodopa (L-dopa), dopamine agonists, monoamine oxidase type B (MAO-B) inhibitors or catechol-O-methyltransferase (COMT) inhibitors, etc., and the therapeutic agents for Huntington's disease use dopamine D2 receptors, etc., but the above therapeutic agents all target the neurotransmission process, and the methods using the above therapeutic agents are only to relieve symptoms, rather than to fundamentally treat the disease. Therefore, there is a continuous need for new drugs that can fundamentally treat diseases. Korean Patent No. 1896398 discloses a substance that can treat neurodegenerative diseases by inhibiting apoptosis of nerve cells.

[0006] The compound of the following Chemical Formula 1 exhibits an activity of promoting the production of nerve growth factor and is a novel compound useful for the treatment of neurological diseases.

[0007] Chemical formula 1

[0008]

[0009] The above compound is a compound isolated from an extract of Hericium erinaceus, and can be used as a fundamental therapeutic agent for neurological diseases including neurodegenerative diseases by promoting the growth of nerve growth factor. However, the preparation method of the above compound is still unknown.

[0010] Under such background, the present inventors studied the synthesis of the above-mentioned compound and developed a method for preparing the compound of the above-mentioned chemical formula 1 and a novel intermediate used in the method, thereby completing the present invention.

[0011] Prior art literature

[0012] Patent Literature

[0013] Korean Patent No. 1896398 Summary of the invention

[0014] Technical issues

[0015] The object of the present invention is to provide a novel compound for synthesizing the compound of the above Chemical Formula 1.

[0016] The object of the present invention is to provide a method for preparing the novel compound.

[0017] The object of the present invention is to provide a method for preparing the compound of Chemical Formula 1 using the novel compound.

[0018] Technical Solution

[0019] The present invention provides compounds of the following Chemical Formula 2 to Chemical Formula 5.

[0020] Chemical formula 2

[0021]

[0022] Chemical formula 3

[0023]

[0024] Chemical formula 4

[0025]

[0026] Chemical formula 5

[0027]

[0028] Furthermore, the present invention provides a method for preparing the compound of the above Chemical Formula 2.

[0029] In one embodiment, the compound of the chemical formula 2 can be prepared by subjecting the 3-hydroxy-5-methoxybenzoic acid methyl ester compound to a Mannich reaction. For example, the Mannich reaction can be to react the 3-hydroxy-5-methoxybenzoic acid methyl ester compound with phenylethylamine and formaldehyde.

[0030] Furthermore, the present invention provides a method for preparing the compound of the above Chemical Formula 3.

[0031] In one embodiment, the compound of the chemical formula 3 can be prepared by reacting the compound of the chemical formula 2 with an acid and then with a base. The acid can be one or more selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid, sulfonic acid and p-toluenesulfonic acid, and the base can be a sodium hydroxide aqueous solution or a potassium hydroxide aqueous solution, but is not limited thereto. Preferably, the acid is hydrochloric acid, and the base is a sodium hydroxide aqueous solution.

[0032] Furthermore, the present invention provides a method for preparing the compound of the above Chemical Formula 4.

[0033] In one embodiment, the compound of the above Chemical Formula 3 may be reacted with an allyl halide to prepare the compound of the above Chemical Formula 4. The above allyl halide may be selected from the group consisting of allyl chloride, allyl bromide and allyl iodide, and is preferably allyl bromide.

[0034] Furthermore, the present invention provides a method for preparing the compound of the above Chemical Formula 5.

[0035] In one embodiment, the compound of the chemical formula 5 may be prepared by subjecting the compound of the chemical formula 4 to a Claisen rearrangement reaction. For example, the reaction may be performed in mesitylene.

[0036] The present invention provides a method for preparing the compound of the following Chemical Formula 1.

[0037] Chemical formula 1

[0038]

[0039] The compound of the above chemical formula 1 is a compound separated and identified from the Hericium erinaceus extract, and can be named as 4-hydroxy-5-(2-hydroxyethyl)-6-methoxy-2-phenylethylisoindolin-1-one, also known as Hericerionol A.

[0040] In one embodiment, the compound of the above chemical formula 1 can be prepared by the following steps: step (a), reacting 3-hydroxy-5-methoxybenzoic acid methyl ester compound with phenylethylamine and formaldehyde to prepare the compound of the above chemical formula 2; and step (b), reacting the compound of the above chemical formula 2 with an acid, and then reacting with a base to prepare the compound of the above chemical formula 3. In step (b), the above acid can be one or more selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid, sulfonic acid and p-toluenesulfonic acid, and the above base can be a sodium hydroxide aqueous solution or a potassium hydroxide aqueous solution, but is not limited thereto. Preferably, the above acid is hydrochloric acid, and the above base is a sodium hydroxide aqueous solution.

[0041] In another embodiment, the compound of the chemical formula 1 may be prepared by further comprising step (c) after the step (b), wherein the step (c) is a step of reacting the compound of the chemical formula 3 with an allyl halide to prepare the compound of the chemical formula 4. The allyl halide may be selected from the group consisting of allyl chloride, allyl bromide and allyl iodide, and is preferably allyl bromide.

[0042] In another embodiment, the compound of the chemical formula 1 may be prepared by further comprising step (d) after the step (c), wherein the step (d) is a step of performing a Claisen rearrangement reaction on the compound of the chemical formula 4 to prepare the compound of the chemical formula 5. In this case, for example, the Claisen rearrangement reaction may be performed under mesitylene.

[0043] In another embodiment, the compound of the above chemical formula 1 may be prepared by the following steps after the above step (d), that is, comprising: step (e), preparing the compound of the following chemical formula 6 by attaching a protective group to the hydroxyl group of the compound of the above chemical formula 5; step (f), performing an oxidation reaction on the compound of the following chemical formula 6 to prepare the compound of the following chemical formula 7; step (g), performing a reduction reaction on the compound of the following chemical formula 7 to prepare the compound of the following chemical formula 8; and step (h), performing a deprotection reaction on the compound of the following chemical formula 8 to prepare the compound of the above chemical formula 1. The oxidation reaction of step (f) may be carried out in the presence of OsO4 or NaIO4. The reduction reaction of step (g) may be carried out in the presence of a suitable reducing agent, for example, in the presence of NaBH4.

[0044] Chemical formula 6

[0045]

[0046] Chemical formula 7

[0047]

[0048] Chemical formula 8

[0049]

[0050] In the above chemical formula, R as a protecting group represents benzoyl, acetyl, methoxymethyl, ethoxyethyl, methylthiomethyl, tert-butyl, allyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, pivaloyl or β-methoxyethoxymethyl.

[0051] When the protecting group R is tert-butyldimethylsilyl, the compounds may be the compounds of Chemical Formula 6, the compounds of Chemical Formula 7a and the compounds of Chemical Formula 8a, respectively.

[0052] Chemical formula 6a

[0053]

[0054] Chemical formula 7a

[0055]

[0056] Chemical formula 8a

[0057]

[0058] The reaction of attaching a protecting group to the hydroxyl group in step (e) and the deprotection reaction in step (h) can be carried out by methods commonly used in the technical field to which the present invention belongs.

[0059] The term "deprotection reaction" used in the present application refers to a reaction in which a hydroxyl group is restored by removing a protecting group bonded to the hydroxyl group in order to protect the hydroxyl group as a reactive group.

[0060] In one embodiment, the attachment reaction of the hydroxyl protecting group in step (e) can use benzoyl, acetyl, methoxymethyl, ethoxyethyl, methylthiomethyl, tert-butyl, allyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, pivaloyl or β-methoxyethoxymethyl, but is not limited thereto.

[0061] For example, in one embodiment, the deprotection reaction in step (h) above may use tetra-n-butylammonium fluoride.

[0062] The preparation method of the compound of Chemical Formula 1 may include the following steps: step (a), reacting 3-hydroxy-5-methoxybenzoic acid methyl ester compound with phenylethylamine and formaldehyde to prepare a compound of Chemical Formula 2; step (b), reacting the compound of Chemical Formula 2 with an acid and then with a base to prepare a compound of Chemical Formula 3; step (c), reacting the compound of the following Chemical Formula 3 with an allyl halide to prepare a compound of the following Chemical Formula 4; step (d): performing a Claisen rearrangement reaction on the compound of Chemical Formula 4 to prepare a compound of Chemical Formula 5; step (e), preparing a compound of Chemical Formula 6 by attaching a protective group to the hydroxyl group of the compound of Chemical Formula 5; step (f), performing an oxidation reaction on the compound of Chemical Formula 6 to prepare a compound of Chemical Formula 7; step (g), performing a reduction reaction on the compound of Chemical Formula 7 to prepare a compound of Chemical Formula 8; and step (h), performing a deprotection reaction on the compound of Chemical Formula 8 to prepare a compound of Chemical Formula 1.

[0063] In one embodiment, the compound of the above Chemical Formula 1 can be prepared by the following Reaction Formula 1.

[0064] Reaction 1

[0065]

[0066] Effects of the Invention

[0067] The present invention can effectively synthesize the compound of the above Chemical Formula 1 by providing a novel compound and a preparation method thereof.

[0068] Furthermore, the compound of the above Chemical Formula 1 synthesized by the method for preparing a novel compound of the present invention can promote the production of nerve growth factor and be usefully used as a therapeutic agent for neurological diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0069] Figure 1 The compound of Chemical Formula 2 is shown 1 H nuclear magnetic resonance (NMR) analysis results.

[0070] Figure 2a and Figure 2b The compound of Chemical Formula 3 is shown 1 H NMR and 13 C NMR analysis results.

[0071] Figure 3a and Figure 3b The compound of Chemical Formula 4 is shown 1 H NMR and 13 C NMR analysis results.

[0072] Figure 4a and Figure 4b The compound of Chemical Formula 5 is shown1 H NMR and 13 C NMR analysis results.

[0073] Figure 5a and Figure 5b The compound of Chemical Formula 6 is shown 1 H NMR and 13 C NMR analysis results.

[0074] Figure 6a and Figure 6b The compound of Chemical Formula 8 is shown 1 H NMR and 13 C NMR analysis results.

[0075] Figure 7a and Figure 7b The compound of Chemical Formula 1 is shown 1 H NMR and 13 C NMR analysis results. DETAILED DESCRIPTION

[0076] Hereinafter, the present invention will be described in more detail by way of examples. However, the following examples are only for the purpose of illustration and are not intended to limit the scope of the present invention.

[0077] Example 1

[0078] Preparation of the compound of formula 2

[0079]

[0080] To a methanol solution (10ml) containing methyl 3-hydroxy-5-methoxybenzoate (4.0g, 21.98mmol), phenylethylamine (4.0mL, 33.03mmol) was added, and a 30% formaldehyde solution (4.0mL) was added dropwise at room temperature. Then, the reaction mixture was warmed to 60°C and stirred for 3 hours. After the reaction was completed (confirmed by thin layer chromatography (TLC)), the reaction mixture was cooled to room temperature and quenched by slowly adding a saturated aqueous solution of sodium bicarbonate. The aqueous layer was extracted three times with ethyl acetate (EtOAc), and the combined organic layer was washed with brine and dried with sodium sulfate. After drying and evaporation, 7-methoxy-3-phenethyl-3,4-dihydro-2H-benzo[e][1,3]oxazine-5-carboxylic acid methyl ester (3.21g, 45%) represented by chemical formula 2 was obtained by column chromatography purification of yellow oil.

[0081] 1H NMR (400MHz,) δ7.32-7.23 (m, 2H), 7.19 (d, J=7.3Hz, 3H), 7.13 (s, 1H), 7.07 (s, 1H), 4.8 5(s, 2H), 4.00(s, 2H), 3.88(s, 3H), 3.84(s, 3H), 3.08-2.95(m, 2H), 2.93-2.77(m, 2H).

[0082] Example 2

[0083] Preparation of the compound of formula 3

[0084]

[0085] 7-Methoxy-3-phenethyl-3,4-dihydro-2H-benzo[e][1,3]oxazine-5-carboxylic acid methyl ester (3.21 g, 9.82 mmol) represented by chemical formula 2 was added to ethanol at room temperature, and HCl was added dropwise to the reaction mixture heated at reflux for 3 hours. After confirming the disappearance of the starting material, the reaction mixture was cooled to 0°C and sodium hydroxide aqueous solution was added until pH 8, and then the reaction mixture was stirred at room temperature for 2 hours. After quenching the reaction with brine (30 mL), it was washed with CHCl3 (3×30 mL). The organic layer was dried with MgSO4, filtered and concentrated. The crude product was purified by column chromatography to obtain 4-hydroxy-6-methoxy-2-phenethylisoindolin-1-one (1.52 g, 55%) as a white solid represented by chemical formula 3.

[0086] 1 H NMR (400MHz,) δ7.27-7.13 (m, 5H), 6.76 (d, J=2.1Hz, 1H), 6.50 (d, J=2.1Hz, 1H), 4.14 (s, 2H), 3.81 (dd, J=9.3, 5.2Hz, 2H), 3.77 (s, 3H), 2.96 (t, J =7.3Hz, 2H).13CNMR (101MHz,) δ169.56, 161.73, 153.10, 138.79, 134.3 1, 128.46, 128.27, 126.21, 120.75, 105.10, 97.57, 54.70, 44.11, 34.20.

[0087] Example 3

[0088] Preparation of the compound of formula 4

[0089]

[0090] To a solution of 4-hydroxy-6-methoxy-2-phenethylisoindolin-1-one (1.50 g, 5.30 mmol) in N,N-dimethylformamide (DMF) represented by Chemical Formula 3, potassium carbonate (2.5 equiv) was added, and then allyl bromide (1.27 g, 10.60 mmol) was added dropwise at room temperature. The reaction mixture was stirred at room temperature for 5 hours. The reaction was quenched by adding a saturated aqueous solution of NaHCO3 (30 mL), and then washed with CHCl3 (3×30 mL). The combined organic layer was dried over MgSO4, filtered, and concentrated. The crude product was purified by silica gel column chromatography (hexane / ether (Et2O), 20:1) to obtain 4-(allyloxy)-6-methoxy-2-phenethylisoindolin-1-one (1.55 g, 91%) as a white solid represented by Chemical Formula 4.

[0091] 1 H NMR (400MHz,) δ7.39-7.14 (m, 5H), 6.92 (d, J=1.9Hz, 1H), 6.54 (d, J=2.0Hz, 1H), 6.06-5.90 (m, 1H), 5.33 (ddd, J=13 .9, 11.9, 1.4Hz, 2H), 4.54 (dt, J=5.3, 1.5Hz, 2H), 4.16 (s, 2H), 3.93-3.76 (m, 5H), 2.96 (dd, J=14.3, 7.1Hz, 2H).13C NMR (101MHz,) δ168.52, 161.63, 154.09, 138.79, 135.21, 132.65, 128.80, 128. 70, 126.58, 122.49, 118.13, 103.33, 98.11, 69.00, 55.93, 48.16, 44.29, 34.93.

[0092] Example 4

[0093] Preparation of the compound of formula 5

[0094]

[0095] 4-(allyloxy)-6-methoxy-2-phenethylisoindolin-1-one (1.55 g, 4.8 mmol) represented by chemical formula 4 was refluxed in mesitylene (10 mL) for one day. After the cooled reaction mixture was concentrated in vacuo, it was dissolved in ethyl acetate (AcOEt) (30 mL). The combined organic layer was washed with a saturated aqueous NaCl solution (100 mL). The organic layer was dried over MgSO4 and then concentrated. The crude product was purified by silica gel chromatography using a mixture of ethyl acetate and hexane (1:3) as an eluent, and 5-allyl-4-hydroxy-6-methoxy-2-phenethylisoindolin-1-one (1.26 g, 84%) as a white solid represented by chemical formula 5 was obtained.

[0096] 1 H NMR (400MHz,) δ7.31-7.15 (m, 5H), 6.97 (s, 1H), 5.95 (ddt, J=16.2, 10.1, 6.1Hz, 1H), 5.2 2-5.04(m, 2H), 4.18(s, 2H), 3.89-3.80(m, 5H), 3.58-3.46(m, 2H), 3.01-2.89(m, 2H).13C NMR (101MHz,) δ168.92, 158.66, 150.25, 138.75, 135.80, 132.70, 128.76, 128. 70, 126.60, 121.06, 116.80, 116.48, 97.93, 56.24, 48.23, 44.35, 34.96, 27.96.

[0097] Example 5

[0098] Preparation of the compound of formula 6

[0099]

[0100] To a solution of 5-allyl-4-hydroxy-6-methoxy-2-phenethylisoindolin-1-one (1.3 g, 4.02 mmol) and 1H imidazole (2.5 equiv) represented by Chemical Formula 5 dissolved in N,N-dimethylformamide (25 mL), tert-butyldimethylsilyl chloride (1.20 g, 8.04 mmol) was added. The reaction mixture was stirred at room temperature for 2 hours. Then, a saturated aqueous solution of NaHCO3 was added to quench the reaction, and CH2Cl2 (3×30 mL) was used for washing. The combined organic layer was dried over MgSO4, filtered, and concentrated. The crude product was purified by silica gel column chromatography (hexane / ether, 20:1) to obtain 5-allyl-4-((tert-butyldimethylsilyl)oxy)-6-methoxy-2-phenethylisoindolin-1-one (1.48 g, 84%) represented by Chemical Formula 6 as a white solid.

[0101] 1 H NMR (400MHz,) δ7.27-7.21 (m, 5H), 7.07-7.02 (m, 1H), 5.95-5.79 (m, 1H), 4.90 (ddd, J=18.8, 13.6, 1.8Hz, 2 H), 3.98 (s, 2H), 3.88-3.83 (m, 5H), 3.44-3.34 (m, 2H), 2.97 (t, J=7.0Hz, 2H), 0.96 (s, 9H), 0.09 (s, 6H).13C NMR (101MHz,) δ168.72, 159.47, 148.67, 144.78, 139.12, 136.03, 132.48, 128.77, 126.63 , 124.24, 123.24, 114.79, 99.29, 56.15, 49.73, 44.25, 35.17, 28.40, 25.98, 18.67, -3.26.

[0102] Example 6

[0103] Preparation of the compound of Chemical Formula 7 and the compound of Chemical Formula 8

[0104]

[0105] After dissolving 5-allyl-4-((tert-butyldimethylsilyl)oxy)-6-methoxy-2-phenethylisoindolin-1-one (1.4 g, 1.20 mmol) represented by Chemical Formula 6 in diethyl ether (24 mL), 0.05 M OsO4 acetone solution (2.5 equiv) was added to the above solution. The resulting thick brown solution was stirred for 1 hour, and after adding water (24 mL) to the above solution, fine powder NaIO4 (1.28 g, 6.0 mmol) was added in 5 portions over 5 hours. After additional stirring of the yellow-brown slurry for 45 minutes, it was diluted with diethyl ether to separate the layers. After washing the organic layer with saturated brine, it was dried with Na2SO4, filtered, and concentrated in vacuo to obtain a crude product represented by Chemical Formula 7.

[0106] The crude product was dissolved in CH3OH (6.0 mL) and cooled to 0°C, and then treated with NaBH4 (1.36 g, 3.60 mmol). After 30 minutes, 10% HCl was added to quench the excess hydride, and the resulting mixture was extracted with ether. The combined organic extracts were washed with saturated brine, dried with Na2SO4, filtered through a SiO2 plug (1.0 in.) on a Celite pad, and concentrated in vacuo to obtain 4-((tert-butyldimethylsilyl)oxy)-5-(2-hydroxyethyl)-6-methoxy-2-phenylethylisoindolin-1-one (437 mg, 31%) as a white solid represented by Chemical Formula 8.

[0107] 1 H NMR (400MHz,) δ7.28-7.10 (m, 5H), 6.99 (s, 1H), 4.86 (s, 2H), 4.00 (s, 2H), 3.90-3.80 ( m, 5H), 3.58-3.50 (m, 2H), 2.98-2.93 (m, 4H), 0.99-0.96 (m, 9H), 0.11-0.09 (m, 6H).13C NMR (101MHz,) δ169.31, 159.85, 149.20, 139.05, 131.84, 128.20, 126.29, 124.60, 12 2.10, 98.32, 96.20, 60.18, 55.10, 50.01, 44.02, 34.39, 27.58, 25.12, 18.18, -4.52.

[0108] Example 7

[0109] Preparation of the compound of formula 1

[0110]

[0111] To a solution of 4-((tert-butyldimethylsilyl)oxy)-5-(2-hydroxyethyl)-6-methoxy-2-phenethylisoindolin-1-one (430 mg, 0.97 mmol) represented by Chemical Formula 8 dissolved in tetrahydrofuran (THF) at a temperature of 0°C, a 1.0 M solution (1.46 mL) of tetra-n-butylammonium fluoride (1.46 mmol) dissolved in tetrahydrofuran was added dropwise. After stirring the above solution at room temperature for 2 hours, a saturated solution of NH4Cl was added. After the above mixture was extracted with diethyl ether, the combined organic layer was dried with Na2SO4, filtered, and concentrated in vacuo to obtain an oil, which was purified by SiO2 chromatography (50% ethyl acetate / hexane) to obtain 4-hydroxy-5-(2-hydroxyethyl)-6-methoxy-2-phenethylisoindolin-1-one (261 mg) represented by Chemical Formula 1 as a pale white solid.

[0112] 1 H NMR (400MHz,) δ7.34-7.19 (m, 5H), 7.19-7.14 (m, 1H), 6.85 (s, 1H), 4.15 (s, 2 H), 3.86-3.79 (m, 5H), 3.64 (t, J=7.0Hz, 2H), 2.96 (td, J=7.1, 1.8Hz, 4H).13C NMR (101MHz,) δ169.72, 159.34, 151.01, 138.80, 131.45, 128.46, 128.29, 126.22, 121.27, 118.33, 96.17, 61.14, 55.01, 48.44, 44.06, 34.24, 26.57.

Claims

1. A compound, It is characterized in that It is represented by the following chemical formula 2: Chemical formula 2:

2. A compound, It is characterized in that It is represented by the following chemical formula 3: Chemical formula 3:

3. A compound, It is characterized in that It is represented by the following chemical formula 4: Chemical formula 4:

4. A compound, It is characterized in that It is represented by the following chemical formula 5: Chemical formula 5:

5. A method for preparing a compound of chemical formula 2, It is characterized in that The compound of the following chemical formula 2 is prepared by reacting 3-hydroxy-5-methoxybenzoic acid methyl ester with phenylethylamine and formaldehyde: Chemical formula 2:

6. A method for preparing a compound of chemical formula 3, It is characterized in that The compound of the following chemical formula 2 is reacted with an acid and then reacted with a base to prepare the compound of the following chemical formula 3: Chemical formula 2: Chemical formula 3:

7. A method for preparing a compound of chemical formula 4, It is characterized in that The compound of the following Chemical Formula 3 is reacted with an allyl halide to prepare the compound of the following Chemical Formula 4: Chemical formula 3: Chemical formula 4:

8. A method for preparing a compound of chemical formula 5, It is characterized in that The compound of the following chemical formula 4 is reacted in mesitylene to prepare the compound of the following chemical formula 5: Chemical formula 4: Chemical formula 5:

9. A method for preparing a compound, wherein the compound is represented by the following chemical formula 1: It is characterized in that include: Step (a), reacting 3-hydroxy-5-methoxybenzoic acid methyl ester with phenylethylamine and formaldehyde to prepare a compound of the following chemical formula 2; Step (b), reacting the compound of the following chemical formula 2 with an acid, and then reacting with a base to prepare a compound of the following chemical formula 3; Step (c), reacting the compound of the following chemical formula 3 with an allyl halide to prepare the compound of the following chemical formula 4; Step (d): reacting the compound of the following chemical formula 4 in mesitylene to prepare the compound of the following chemical formula 5; Step (e), preparing a compound of the following Chemical Formula 6 by attaching a protective group to the hydroxyl group of the compound of the following Chemical Formula 5; Step (f), subjecting the compound of the following chemical formula 6 to an oxidation reaction to prepare the compound of the following chemical formula 7; Step (g), subjecting the compound of the following chemical formula 7 to a reduction reaction to prepare the compound of the following chemical formula 8; and Step (h), performing a deprotection reaction on the compound of the following chemical formula 8 to prepare the compound of the following chemical formula 1, Chemical formula 1: Chemical formula 2: Chemical formula 3: Chemical formula 4: Chemical formula 5: Chemical formula 6: Chemical formula 7: Chemical formula 8: In the above chemical formula, R as a protecting group represents benzoyl, acetyl, methoxymethyl, ethoxyethyl, methylthiomethyl, tert-butyl, allyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, pivaloyl or β-methoxyethoxymethyl.

10. The method for preparing the compound of Chemical Formula 3 according to claim 6, It is characterized in that The acid is at least one selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid, sulfonic acid and p-toluenesulfonic acid, and the base is an aqueous sodium hydroxide solution or an aqueous potassium hydroxide solution.

11. The method for preparing the compound according to claim 9, wherein the compound is represented by Chemical Formula 1: It is characterized in that In step (b), the acid is at least one selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid, sulfonic acid and p-toluenesulfonic acid, and the base is an aqueous sodium hydroxide solution or an aqueous potassium hydroxide solution.

12. The method for preparing the compound of Chemical Formula 4 according to claim 7, It is characterized in that The allyl halide is selected from the group consisting of allyl chloride, allyl bromide and allyl iodide.

13. The method for preparing the compound according to claim 9, wherein the compound is represented by Chemical Formula 1: It is characterized in that In step (c), the allyl halide is selected from the group consisting of allyl chloride, allyl bromide and allyl iodide.